InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,477.90
(
0.16%
)
US TECH 100
19,172.40
(
-0.22%
)
Dow Jones
39,127.80
(
0.04%
)
Brent Oil
85.06
(
0.69%
)
Bitcoin
60,886.15
(
0.12%
)
Post# of 19309
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 833
Posts 119931
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: Lewis R Goudy post# 1722

Friday, 11/03/2006 9:18:31 PM

Friday, November 03, 2006 9:18:31 PM

Post# of 19309
>ART-123 uniquely targets both coagulation and systemic inflammatory pathways...Is that true?<

It’s true if you take out the word uniquely. If you leave uniquely in, then it’s a line-drawing game.

>Atryn's anti-inflammatory properties are not in that category?<

The MoA of ART-123/thrombomodulin is similar to that of antithrombin because the molecule is a fragment of antithrombin. However, I think it’s reasonable to expect that ART-123 will have a more difficult U.S. regulatory path than ATryn because ART-123 is not structurally close enough to plasma antithrombin for the FDA to presume that it will work the same way.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up